Progesterone against progestin, and the trial arm that decides how you read the headline

What is the difference between progesterone and progestin?

Progesterone is a hormone the ovary produces after ovulation, and a progestin is a synthetic drug built to act on the same receptor without being the same molecule. Both act on the progesterone receptor and both oppose the growth that estrogen drives in the lining of the uterus, which is the job a menopause regimen prescribes them for. Medroxyprogesterone acetate, sold as Provera, is the progestin used in the Women's Health Initiative estrogen plus progestin trial, and micronized progesterone, sold as Prometrium, was not used in that trial at all.

Micronized progesterone sold as Prometrium and medroxyprogesterone acetate sold as Provera are both FDA-approved products with published labels. Compounded progesterone preparations, which 3 of the platforms we price-verify dispense, are mixed by a pharmacy rather than approved by the FDA and carry no registration trial. What bioidentical actually means.

Why a progestogen is in the regimen at all

Estrogen tells the lining of the uterus to grow. In a woman who still has one, months of that growth with nothing holding it back is the route to hyperplasia and then to endometrial cancer, which is why a second drug goes into the regimen. The estradiol labels state the rule in the dosage section rather than in fine print.

“Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, consider addition of a progestogen to reduce the risk of endometrial cancer. Generally, a woman without a uterus does not need to use a progestogen in addition to her estrogen therapy.”From the DOSAGE AND ADMINISTRATION section of the FDA-approved vaginal estradiol insert labels. The word the labels use is progestogen, which covers progesterone and every progestin at once, which is where the confusion on this page starts.

The size of the protection is printed on the Prometrium label: hyperplasia or worse in 6 percent of the arm on conjugated estrogens plus progesterone against 64 percent on the same estrogen alone, over 36 months, with a placebo arm at 3 percent. The full table, with the atypical and complex hyperplasia rows, is on the progesterone hub. Nothing on this page contradicts it.

On that job the two are interchangeable by indication, and the two labels say it in nearly the same words. Prometrium's INDICATIONS AND USAGE section reads: “Prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets, and treatment of secondary amenorrhea.” Provera's reads: “Treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, and prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving daily oral conjugated estrogens 0.625 mg tablets.” The endometrial clause is the same clause. Provera adds abnormal uterine bleeding, which the progesterone label does not carry, and spells out the estrogen dose the indication is scoped to.

Read those two sentences again and something else falls out of them. Both are written against a woman receiving conjugated estrogens tablets, and neither names estradiol, which is the estrogen every platform on our roster that names one dispenses. That is not a warning. Estradiol with progesterone is FDA-approved in its own right as Bijuva (estradiol and progesterone) capsules, whose own indication reads: “Bijuva is a combination of an estrogen and progesterone indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause.” It is a detail about how these labels are worded, and it matters later on this page, because the trial everyone quotes used conjugated estrogens too.

So the question is never whether you need a progestogen. If you take systemic estrogen and you have a uterus, you need one. The question is which one, and that is the question the labels leave to the person writing your prescription.

What is established, and what is observational

Since no trial randomized women to one progestogen against the other, the claim that micronized progesterone carries a lower breast cancer risk rests on cohort studies, and the one everyone is quoting is E3N. It is a real study with a large sample. It is also observational, and two of its four rows have confidence intervals that cross 1.00, which is the part that disappears when the finding is retold.

French E3N prospective cohort, biennial self-administered questionnaires from 1990 to 2002, 80,377 postmenopausal women, 2,354 invasive breast cancers over a mean 8.1 postmenopausal years. Comparator is never-use of hormone replacement therapy. Fournier A, Berrino F, Clavel-Chapelon F, Breast Cancer Res Treat 2008, PMID 17333341, read 2026-08-16. The paper carries an erratum at Breast Cancer Res Treat 2008;107(2):307-8, which is not indexed as a separate PubMed record and could not be retrieved on that date. The figures above are those in the PubMed abstract as it currently stands.

Read the table rather than the summary of it. 2 of the 4 rows have intervals compatible with no effect, and the 1.00 that gets quoted for estrogen with progesterone is one of them. What the data separates cleanly is the top row from the bottom row: estrogen with other progestagens at 1.69, interval 1.50 to 1.91. The authors also flagged that this bottom category is not one drug. This latter category involves progestins with different physiologic activities (androgenic, nonandrogenic, antiandrogenic), but their associations with breast cancer risk did not differ significantly from one another.

The guideline position is narrower than either camp wants it to be. The Menopause Society 2022 position statement says: “The risks of hormone therapy differ depending on type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is used.” Type is on that list. So are dose, duration, route and timing, and the statement says whether a progestogen is used rather than which one. Read as written, it supports treating the two as non-interchangeable and it does not rank them.

What the labels say today, checked this week

The FDA announced removal of the boxed warnings from menopause hormone therapy in November 2025 and approved the labeling changes in February 2026. That second date is on the public record: the Drugs@FDA record for the Prometrium application carries a labeling supplement approved February 12, 2026. Manufacturers repost on their own schedule, so the only way to know what a given label says is to open it. We counted the boxed warning section in the structured label data for all three drugs on 2026-08-16.

Method: Sections carrying LOINC 34066-1 (BOXED WARNING SECTION) counted in the DailyMed SPL XML. 2 of the 3 return at least one section and 1 returns none, so the method detects the section where it exists, which is what makes the single absence a finding rather than a failed read. Provera returns two because that labeler codes the boxed warning twice, once in the prescribing information and once in the patient package insert. Premarin codes only the prescribing-information copy, so the raw number reports a coding choice on top of the warning itself.

What is not ambiguous is the wording on the one label that still names the regimen. The Provera boxed warning is titled WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER AND PROBABLE DEMENTIA FOR ESTROGEN PLUS PROGESTIN THERAPY, and its body cites the trial directly: The Women's Health Initiative estrogen plus progestin substudy reported an increased risk of deep vein thrombosis, pulmonary embolism, stroke and myocardial infarction in postmenopausal women 50 to 79 years of age during 5.6 years of treatment with daily oral conjugated estrogens 0.625 mg combined with medroxyprogesterone acetate 2.5 mg, relative to placebo. The estrogen plus progestin substudy demonstrated an increased risk of invasive breast cancer. Read the title again. It names estrogen plus progestin therapy. The umbrella word progestogen, the one that would cover progesterone too, does not appear in it.

The same label then sets its own limit on how far the finding travels: “In the absence of comparable data, these risks should be assumed to be similar for other doses of conjugated estrogens and medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins.” In the absence of comparable data is the operative clause. The label is extending a result rather than reporting one, and it says so.

Prometrium (progesterone, USP) capsules is the label with no boxed warning section in this check. What the black box change did and did not do, and the approval records: Provera NDA011839, Premarin NDA004782, Prometrium NDA019781.

The two ingredient lists rule out different people

The choice between the molecules can come down to what the medicine is carried in, and the two labels differ there. Prometrium capsules contain peanut oil and are contraindicated in patients allergic to peanuts. That sits in CONTRAINDICATIONS and is repeated on the patient leaflet. Provera is a tablet, and its inactive ingredients are a different list: calcium stearate, corn starch, lactose, mineral oil, sucrose and talc. A peanut allergy and a lactose intolerance rule out different products, and neither list is on the formulary page you are shopping from.

How progesterone is dosed, and the sedation the label warns about is on the progesterone hub rather than repeated here, and the progesterone side-effect table with its placebo column is the next thing to read if tolerability is what you are weighing.

Estradiol against estrogen, the same mistake one level up

The progesterone and progestin confusion has an exact twin on the other half of the prescription. Estrogen is a class of hormones. Estradiol is one molecule inside that class, alongside estrone and estriol. A product that says estrogen has told you the class without telling you the molecule, and the difference is printed on the label of the product both WHI arms used.

“Premarin tablets for oral administration contain a mixture of conjugated estrogens purified from pregnant mares' urine, consisting of the sodium salts of water-soluble estrogen sulfates blended to represent the average composition of material derived from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium equilin sulfate, with concomitant components as sodium sulfate conjugates: 17-alpha-dihydroequilin, 17-alpha estradiol and 17-beta-dihydroequilin.”Premarin (conjugated estrogens) tablets, USP DESCRIPTION section, SPL posted 2026-06-04, read 2026-08-16. Strengths 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg and 1.25 mg.

That is a mixture harvested from a biological source, standardised to an average composition. Estradiol is a single molecule, chemically identical to what the ovary produces, which is what the word bioidentical is pointing at when it is used accurately. Both are estrogens. They are not the same drug, and both WHI arms used the mixture rather than the molecule.

Which puts the whole trial at two removes from a current prescription. The estrogen in it was conjugated equine estrogens rather than estradiol, and the progestogen in the arm that produced the headline was a progestin rather than progesterone. That is not an argument that modern hormone therapy is risk-free. It is an argument for reading which drugs a study tested before you carry its conclusion to a different pair. Estradiol by delivery form, with what each one costs, is the practical version of this section.

Which platform tells you which molecule you get

If the distinction on this page decides anything, it decides what to ask before you pay. So here is the same question put to every platform we track. 8 of the 13women's-wing platforms dispense a progestogen. 3 name which one in their published formulary and 5 print the word progesterone and stop. Each line below is the provider's own product string, kept verbatim including its verification label.

Not specified is the honest reading of a formulary that says progesterone without saying which. It is not an accusation, and a clinician will answer it in one question on the intake call. What it means is that the answer is not on the page you are deciding from. What each of them charges for it is on the progesterone hub, and the price-sorted table covers the platform price beside it.

Who else is answering this question

Worth knowing before you weigh any page on this topic, including this one. A search for the exact phrase “progesterone vs progestin” on 2026-08-16 returned 9 results on the first page. 3 of them are hormone platforms on our own roster: Hers Menopause, Winona and Elektra Health. Of the rest, 2 are practitioner sites, 2 are health publishers, 1 is a clinic and 1 is a fertility products retailer.

A platform that sells compounded progesterone explaining why progesterone differs from a progestin is not lying. It is answering a question whose answer decides which of its products you buy, which is the position this site exists to sit outside of. We take no money for rankings and the scoring rubric is published in full. How the scores are built and how we are paid.

First page of results for the exact phrase, United States. Domains recorded, positions not recorded. Positions are deliberately not claimed, and a search run from a different location on a different day will return a different set.

Related

• Progesterone, and the number that explains why it is in your regimen the endometrial protection table, and what each platform charges
• Estradiol, explained and then priced the other half of the regimen
• Is HRT safe, in absolute numbers by age
• What bioidentical actually means
• The black box warning change, precisely
• The scored provider rankings and cheapest verified HRT